文献速递临床试验与 GCP

氯胺酮治疗创伤后急性疼痛:KAPT随机对照试验

Ketamine for acute pain after trauma: the KAPT randomized controlled trial.
PubMed 文献 · Trials · 2022-07-27

本研究为单中心、平行组、随机对照实效比较试验,比较以片剂为基础、减少阿片类药物的多模式镇痛方案(MMPR)与MMPR联合亚解离剂量氯胺酮输注在成年创伤患者中的效果。主要结局为每患者每日吗啡毫克当量(MME/患者/日),次要结局包括总MME、疼痛评分、并发症、住院时间、出院时阿片类药物处方及出院和6个月时以患者为中心的结局。

要点

  • 在减少阿片类药物暴露的多模式镇痛方案基础上加用亚解离剂量氯胺酮,评估其对创伤后急性疼痛患者阿片类药物使用的影响。
  • 主要结局为每患者每日吗啡毫克当量(MME/患者/日),次要结局涵盖疼痛评分、并发症、住院时间及患者报告结局。
  • 试验纳入16岁及以上、需中级或重症监护的创伤患者,排除囚犯、孕妇、预期无法存活及有氯胺酮禁忌者。

核心结论

  • 该试验旨在确定亚解离剂量氯胺酮输注作为多模式镇痛方案的一部分,在减少成年创伤患者住院期间阿片类药物暴露方面的有效性。
  • 试验结果将为急性疼痛策略对以患者为中心的结局的影响提供决策依据。

研究设计与样本

  • 单中心、平行组、随机对照实效比较试验,比较MMPR与MMPR联合亚解离剂量氯胺酮输注。
  • 纳入16岁及以上、因创伤入院且需中级或重症监护的创伤患者;排除囚犯、孕妇、预期无法存活及有氯胺酮禁忌者。

关键数值与推荐

  • 主要结局为每患者每日吗啡毫克当量(MME/患者/日)。
  • 次要结局包括总MME、疼痛评分、并发症、住院时间、出院时阿片类药物处方及出院和6个月时以患者为中心的结局。
  • 试验注册号NCT04129086,注册日期2019年10月16日。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence for effective pain management and opioid minimization of intravenous ketamine in elective surgery has been extrapolated to acutely injured patients, despite limited supporting evidence in this population. This trial seeks to determine the effectiveness of the addition of sub-dissociative ketamine to a pill-based, opioid-minimizing multi-modal pain regimen (MMPR) for post traumatic pain. METHODS: This is a single-center, parallel-group, randomized, controlled comparative effectiveness trial comparing a MMPR to a MMPR plus a sub-dissociative ketamine infusion. All trauma patients 16 years and older admitted following a trauma which require intermediate (IMU) or intensive care unit (ICU) level of care are eligible. Prisoners, patients who are pregnant, patients not expected to survive, and those with contraindications to ketamine are excluded from this study. The primary outcome is opioid use, measured by morphine milligram equivalents (MME) per patient per day (MME/patient/day). The secondary outcomes include total MME, pain scores, morbidity, lengths of stay, opioid prescriptions at discharge, and patient centered outcomes at discharge and 6 months. DISCUSSION: This trial will determine the effectiveness of sub-dissociative ketamine infusion as part of a MMPR in reducing in-hospital opioid exposure in adult trauma patients. Furthermore, it will inform decisions regarding acute pain strategies on patient centered outcomes. TRIAL REGISTRATION: The Ketamine for Acute Pain Management After Trauma (KAPT) with registration # NCT04129086 was registered on October 16, 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Puzio TJ, Klugh J, Wandling MW, et al. Ketamine for acute pain after trauma: the KAPT randomized controlled trial. Trials. 2022. PMID: 35897081. doi:10.1186/s13063-022-06511-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。